Literature DB >> 32020325

Concordance Study in Hepatectomy Recommendations Between Watson for Oncology and Clinical Practice for Patients with Hepatocellular Carcinoma in China.

Weiqi Zhang1, Shuo Qi1, Jiaming Zhuo1, Sai Wen1, Chihua Fang2.   

Abstract

BACKGROUND: With the improvement in diagnostic imaging, perioperative care and surgical technique, the indications and complexity of liver resections have developed. However, the surgical indications remain controversial especially for some complex or advanced hepatocellular carcinomas. This study was designed to evaluate the concordance between hepatectomy recommendations proposed by Watson for Oncology, a cognitive technology providing decision support, and those determined by surgeons in our center for patients with hepatocellular carcinoma.
METHODS: We retrospectively reviewed 243 patients with hepatocellular carcinoma who were recommended for surgical treatment and received hepatectomy between 2008 and 2016 at the Zhujiang Hospital of Southern Medical University. Watson for Oncology classified the treatment options into three categories: recommended, for consideration and not recommended. Treatment recommendations were considered concordant if the hepatectomy recommendations were designated "recommended" or "for consideration" by Watson for Oncology. The factors potentially affecting concordance rate were also analyzed in our study.
RESULTS: The hepatectomy recommendations of 174 patients were concordant. There were significant differences in the coincidence rate between concordant group and discordant group considering tumor numbers (P = 0.006), extension of hepatectomy (P = 0.009) and BCLC staging system (P < 0.001). Lower degrees of concordance were observed in patients with multiple tumors, major hepatectomy and portal hypertension by using logistic regression analysis (OR = 0.309, P = 0.004; OR = 0.384, P = 0.004; and OR = 0.376, P = 0.022, respectively).
CONCLUSION: The concordance between Watson for Oncology and surgeons' hepatectomy recommendation for hepatocellular carcinoma was only 72%. Differences in practice patterns for HCC between the USA (where Watson for Oncology was calibrated) and China may be the major cause of discordance. Watson for Oncology still requires further improvement and localization to be widely applied in China.

Entities:  

Year:  2020        PMID: 32020325     DOI: 10.1007/s00268-020-05401-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Accuracy of Decision Support Systems for Breast Cancer - Initial Results.

Authors:  Priscyla Waleska Simões; Ronaldo Borges Vicente; Patrícia Duarte Simões Pires; Maria Marlene de Souza Pires; Eros Comunello; Felipe Borges Tomaz; Luciane Bisognin Ceretta; Deborah Ribeiro de Carvalho
Journal:  Stud Health Technol Inform       Date:  2017

2.  The hepatitis B epidemic in China should receive more attention.

Authors:  Shanquan Chen; Jun Li; Dan Wang; Hong Fung; Lai-Yi Wong; Lu Zhao
Journal:  Lancet       Date:  2018-04-21       Impact factor: 79.321

3.  Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.

Authors:  S P Somashekhar; M-J Sepúlveda; S Puglielli; A D Norden; E H Shortliffe; C Rohit Kumar; A Rauthan; N Arun Kumar; P Patil; K Rhee; Y Ramya
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 32.976

4.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

5.  A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.

Authors:  Guido Torzilli; Jacques Belghiti; Norihiro Kokudo; Tadatoshi Takayama; Lorenzo Capussotti; Gennaro Nuzzo; Jean-Nicolas Vauthey; Michael A Choti; Eduardo De Santibanes; Matteo Donadon; Emanuela Morenghi; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2013-05       Impact factor: 12.969

6.  Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT.

Authors:  Lei Yin; Hui Li; Ai-Jun Li; Wan Yee Lau; Ze-Ya Pan; Eric C H Lai; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Hepatol       Date:  2014-03-17       Impact factor: 25.083

Review 7.  The global burden of liver disease: the major impact of China.

Authors:  Fu-Sheng Wang; Jian-Gao Fan; Zheng Zhang; Bin Gao; Hong-Yang Wang
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

Review 8.  Artificial Intelligence in Surgery: Promises and Perils.

Authors:  Daniel A Hashimoto; Guy Rosman; Daniela Rus; Ozanan R Meireles
Journal:  Ann Surg       Date:  2018-07       Impact factor: 12.969

9.  Using OncoDoc as a computer-based eligibility screening system to improve accrual onto breast cancer clinical trials.

Authors:  Brigitte Séroussi; Jacques Bouaud
Journal:  Artif Intell Med       Date:  2003 Sep-Oct       Impact factor: 5.326

10.  A new era of oncology through artificial intelligence.

Authors:  Alessandra Curioni-Fontecedro
Journal:  ESMO Open       Date:  2017-05-15
View more
  2 in total

1.  Application of Absorbable Suture in Strabismus Correction and Nursing Management Advantage of Watson Care Theory in Perioperative Period.

Authors:  Weina Guo; Suling Yang; Yuexing Gong; Lizhi Zhang; Tao Jin; Jiancang Wang; Xiting Guo; Huihui Sun; Yanxia Song; Haixia Tian
Journal:  Comput Math Methods Med       Date:  2022-03-04       Impact factor: 2.238

2.  Long noncoding RNA MACC1-AS1 promotes the stemness of hepatocellular carcinoma cells by antagonizing miR-145.

Authors:  Yuling Guo; Jiuhong Zhong; Fang Wu; Zhengyu Zhan
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.